imatinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1423 152459-95-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imatinib
  • gleevec
  • imatinib mesylate
  • imatinib mesilate
  • CGP-57-148B
  • CGP57148B
  • CGP-57148
  • CGP57148
  • STI-571
  • STI571
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
  • Molecular weight: 493.62
  • Formula: C29H31N7O
  • CLOGP: 4.38
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 86.28
  • ALOGS: -4.53
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.26 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 10, 2001 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1435.05 12.83 1542 36073 334006 46314441
Gastrointestinal stromal tumour 792.56 12.83 184 37431 956 46647491
Chronic myeloid leukaemia 753.32 12.83 206 37409 2252 46646195
Blast crisis in myelogenous leukaemia 625.31 12.83 131 37484 377 46648070
Cytogenetic analysis abnormal 497.60 12.83 111 37504 465 46647982
Drug resistance 442.58 12.83 235 37380 17133 46631314
Second primary malignancy 404.37 12.83 164 37451 6420 46642027
Malignant neoplasm progression 395.75 12.83 364 37251 64562 46583885
Periorbital oedema 277.20 12.83 116 37499 4919 46643528
Gene mutation identification test positive 243.48 12.83 49 37566 107 46648340
Neoplasm malignant 220.17 12.83 169 37446 23330 46625117
Philadelphia chromosome positive 190.62 12.83 45 37570 254 46648193
Chromosome analysis abnormal 181.18 12.83 38 37577 110 46648337
Leukaemia recurrent 175.52 12.83 58 37557 1251 46647196
Chronic myeloid leukaemia recurrent 163.24 12.83 37 37578 169 46648278
Muscle spasms 161.77 12.83 326 37289 122787 46525660
Rheumatoid arthritis 157.38 12.83 9 37606 240206 46408241
Oedema 156.13 12.83 229 37386 66842 46581605
Acute lymphocytic leukaemia recurrent 155.98 12.83 60 37555 2035 46646412
Pleural effusion 155.11 12.83 256 37359 82696 46565751
Chronic myeloid leukaemia transformation 141.74 12.83 30 37585 92 46648355
Gastric antral vascular ectasia 138.34 12.83 40 37575 542 46647905
Eye swelling 130.68 12.83 117 37498 19986 46628461
Eyelid oedema 118.39 12.83 84 37531 10273 46638174
Bone marrow failure 107.48 12.83 126 37489 29543 46618904
Fluid retention 105.56 12.83 165 37450 50881 46597566
Completed suicide 93.88 12.83 6 37609 145914 46502533
Drug hypersensitivity 91.53 12.83 41 37574 243784 46404663
Pancytopenia 90.61 12.83 207 37408 84851 46563596
Rash 88.33 12.83 539 37076 355973 46292474
Face oedema 87.76 12.83 92 37523 19061 46629386
Conjunctival haemorrhage 86.38 12.83 44 37571 2937 46645510
Nausea 82.74 12.83 880 36735 686574 45961873
Oedema peripheral 82.17 12.83 299 37316 159407 46489040
Gene mutation 80.65 12.83 31 37584 1049 46647398
Pseudoporphyria 79.02 12.83 20 37595 157 46648290
Normal newborn 78.77 12.83 53 37562 5948 46642499
Anaemia 77.98 12.83 409 37206 255370 46393077
Product substitution issue 77.60 12.83 77 37538 14954 46633493
Blast cell crisis 75.86 12.83 16 37599 48 46648399
Metastases to liver 75.67 12.83 86 37529 19499 46628948
Growth retardation 73.42 12.83 28 37587 927 46647520
Cytogenetic abnormality 72.78 12.83 24 37591 514 46647933
Graft versus host disease 72.00 12.83 52 37563 6536 46641911
Generalised oedema 71.09 12.83 72 37543 14327 46634120
Thrombocytosis 67.63 12.83 45 37570 4957 46643490
Swelling face 66.59 12.83 138 37477 52921 46595526
Acute lymphocytic leukaemia 66.32 12.83 36 37579 2737 46645710
Recurrent cancer 66.07 12.83 31 37584 1728 46646719
Off label use 66.02 12.83 129 37486 379712 46268735
Exposure via father 65.46 12.83 20 37595 331 46648116
Disease progression 63.09 12.83 189 37426 91111 46557336
Haematotoxicity 60.86 12.83 48 37567 6885 46641562
Hepatotoxicity 60.47 12.83 87 37528 24922 46623525
Chronic graft versus host disease 58.64 12.83 33 37582 2692 46645755
Splenomegaly 58.28 12.83 54 37561 9634 46638813
Hypotension 58.15 12.83 61 37554 232528 46415919
Fall 57.82 12.83 111 37504 328986 46319461
Polymerase chain reaction positive 56.17 12.83 12 37603 39 46648408
Thrombocytopenia 55.22 12.83 225 37390 126356 46522091
Neoplasm progression 54.78 12.83 86 37529 26597 46621850
Pain 52.82 12.83 202 37413 476746 46171701
Bone pain 51.99 12.83 116 37499 46774 46601673
Neoplasm recurrence 51.78 12.83 29 37586 2344 46646103
Pericardial effusion 50.61 12.83 81 37534 25462 46622985
Arthropathy 50.23 12.83 5 37610 84695 46563752
Therapy non-responder 49.26 12.83 105 37510 41047 46607400
Therapeutic response decreased 48.13 12.83 107 37508 43038 46605409
Leukaemia 47.85 12.83 31 37584 3264 46645183
Drug intolerance 47.39 12.83 239 37376 146810 46501637
Exposure via body fluid 47.23 12.83 17 37598 477 46647970
Vomiting 46.62 12.83 563 37052 452231 46196216
Metastases to peritoneum 46.23 12.83 28 37587 2620 46645827
Eye haemorrhage 45.73 12.83 41 37574 7011 46641436
Urinary tract infection 44.40 12.83 68 37547 220198 46428249
Cardiac output decreased 43.54 12.83 19 37596 893 46647554
Chordoma 42.87 12.83 7 37608 0 46648447
Haemoglobin decreased 42.54 12.83 211 37404 128738 46519709
Eye oedema 41.61 12.83 21 37594 1374 46647073
Psoriasis 40.96 12.83 7 37608 78597 46569850
Overdose 40.05 12.83 16 37599 101963 46546484
Diarrhoea 39.54 12.83 651 36964 558951 46089496
Platelet count increased 39.30 12.83 54 37561 14820 46633627
White blood cell count increased 38.89 12.83 100 37515 44119 46604328
Confusional state 37.65 12.83 44 37571 159848 46488599
Erythrocyanosis 36.75 12.83 6 37609 0 46648447
Blast cells present 36.34 12.83 13 37602 358 46648089
Therapeutic product effect decreased 35.79 12.83 11 37604 82590 46565857
Chloroma 35.78 12.83 11 37604 186 46648261
Neutropenia 35.59 12.83 217 37398 142987 46505460
Therapeutic response delayed 34.81 12.83 14 37601 535 46647912
Exposure via partner 34.41 12.83 10 37605 138 46648309
Skin fragility 33.86 12.83 14 37601 575 46647872
Myalgia 33.47 12.83 191 37424 122897 46525550
Tumour excision 33.36 12.83 12 37603 336 46648111
Platelet count decreased 33.20 12.83 164 37451 99860 46548587
Condition aggravated 33.08 12.83 95 37520 244957 46403490
Acute kidney injury 32.90 12.83 90 37525 235765 46412682
Ascites 32.44 12.83 83 37532 36501 46611946
Sinusitis 32.43 12.83 34 37581 129734 46518713
Bone marrow oedema 32.14 12.83 15 37600 826 46647621
Bone marrow transplant 32.12 12.83 14 37601 656 46647791
Myelofibrosis 31.94 12.83 17 37598 1242 46647205
Pneumatosis intestinalis 31.76 12.83 20 37595 2005 46646442
White blood cell count decreased 31.73 12.83 176 37439 112055 46536392
Systemic lupus erythematosus 31.44 12.83 7 37608 65173 46583274
Pulse waveform abnormal 30.64 12.83 8 37607 72 46648375
Trisomy 8 30.62 12.83 5 37610 0 46648447
Ankle brachial index decreased 30.54 12.83 8 37607 73 46648374
Carotid intima-media thickness increased 30.06 12.83 8 37607 78 46648369
Leukocytosis 29.51 12.83 61 37554 23337 46625110
Intentional overdose 29.33 12.83 8 37607 64936 46583511
Asthma 29.03 12.83 19 37596 91523 46556924
Blood lactate dehydrogenase increased 28.91 12.83 56 37559 20444 46628003
Cardiotoxicity 28.51 12.83 31 37584 6691 46641756
Pyrexia 28.44 12.83 416 37199 348386 46300061
Breast cancer 28.41 12.83 91 37524 45427 46603020
Toxic skin eruption 28.35 12.83 42 37573 12345 46636102
Jaundice 28.27 12.83 68 37547 28777 46619670
Loss of personal independence in daily activities 27.86 12.83 6 37609 57177 46591270
Right ventricular failure 27.81 12.83 48 37567 16045 46632402
Typhoid fever 27.74 12.83 6 37609 21 46648426
Gastrointestinal toxicity 27.72 12.83 25 37590 4306 46644141
Aplasia 27.66 12.83 23 37592 3553 46644894
Morphoea 27.31 12.83 10 37605 295 46648152
Dizziness 27.14 12.83 162 37453 340252 46308195
Left ventricular dysfunction 26.74 12.83 37 37578 10218 46638229
Syncope 26.70 12.83 27 37588 104776 46543671
Blast cell count increased 25.67 12.83 10 37605 351 46648096
Surgery 25.20 12.83 65 37550 28720 46619727
Anxiety 24.94 12.83 70 37545 181887 46466560
Tumour haemorrhage 24.80 12.83 15 37600 1400 46647047
Somnolence 24.71 12.83 56 37559 156465 46491982
Transdifferentiation of neoplasm 24.51 12.83 5 37610 12 46648435
Pubertal failure 24.51 12.83 5 37610 12 46648435
Peritoneal lesion 24.50 12.83 4 37611 0 46648447
Slit-lamp tests abnormal 24.50 12.83 4 37611 0 46648447
Lower respiratory tract infection 24.48 12.83 7 37608 55082 46593365
Inappropriate schedule of product administration 24.24 12.83 11 37604 65002 46583445
Back pain 23.77 12.83 88 37527 209951 46438496
Blood pressure increased 23.72 12.83 41 37574 126625 46521822
Urine odour abnormal 23.02 12.83 24 37591 4938 46643509
Agitation 22.91 12.83 8 37607 55407 46593040
Abortion 22.87 12.83 17 37598 2233 46646214
Hallucination 22.84 12.83 6 37609 49945 46598502
Nasopharyngitis 22.80 12.83 57 37558 153941 46494506
Injury 22.76 12.83 4 37611 44023 46604424
Peripheral arterial occlusive disease 22.73 12.83 21 37594 3731 46644716
Hyponatraemia 22.66 12.83 29 37586 101303 46547144
Hepatic necrosis 22.32 12.83 25 37590 5576 46642871
Suicidal ideation 21.88 12.83 9 37606 56373 46592074
Cytopenia 21.73 12.83 29 37586 7739 46640708
Papilloedema 21.63 12.83 20 37595 3557 46644890
Exposure during pregnancy 21.43 12.83 155 37460 108057 46540390
Blood test abnormal 21.39 12.83 32 37583 9488 46638959
Leukopenia 21.22 12.83 110 37505 68233 46580214
Tumour necrosis 21.18 12.83 11 37604 764 46647683
Abortion spontaneous 20.95 12.83 80 37535 43566 46604881
Gastric cancer 20.94 12.83 18 37597 2911 46645536
Basophilia 20.84 12.83 4 37611 6 46648441
Periorbital swelling 20.81 12.83 13 37602 1285 46647162
Chylothorax 20.80 12.83 8 37607 271 46648176
Lacrimation increased 20.76 12.83 42 37573 15819 46632628
Joint swelling 20.52 12.83 67 37548 166006 46482441
Chronic graft versus host disease in skin 20.44 12.83 10 37605 612 46647835
Tremor 20.25 12.83 39 37576 115600 46532847
Product use issue 20.23 12.83 28 37587 94616 46553831
Intracardiac mass 20.13 12.83 5 37610 36 46648411
Oral pigmentation 20.11 12.83 4 37611 8 46648439
Drug ineffective 20.02 12.83 406 37209 677432 45971015
Blister 19.96 12.83 80 37535 44551 46603896
Musculoskeletal stiffness 19.96 12.83 30 37585 97963 46550484
Anaphylactic reaction 19.78 12.83 9 37606 53103 46595344
Flushing 19.69 12.83 14 37601 64600 46583847
Arthritis 19.60 12.83 20 37595 77296 46571151
Stem cell transplant 19.43 12.83 14 37601 1752 46646695
Loss of consciousness 19.39 12.83 36 37579 108202 46540245
Swelling of eyelid 19.28 12.83 12 37603 1179 46647268
Computerised tomogram abnormal 18.93 12.83 15 37600 2165 46646282
Acute myeloid leukaemia 18.57 12.83 40 37575 15738 46632709
Neoplasm 18.37 12.83 23 37592 5765 46642682
Influenza like illness 18.18 12.83 12 37603 57558 46590889
Myelocytosis 18.07 12.83 4 37611 16 46648431
Insomnia 18.07 12.83 70 37545 164854 46483593
Cellulitis 18.02 12.83 18 37597 70270 46578177
Urticaria 17.94 12.83 43 37572 117849 46530598
Pulmonary embolism 17.83 12.83 38 37577 108547 46539900
Aspiration pleural cavity 17.82 12.83 10 37605 811 46647636
Headache 17.75 12.83 275 37340 478077 46170370
Deep vein thrombosis 17.66 12.83 23 37592 79750 46568697
Liver disorder 17.65 12.83 68 37547 37178 46611269
Dengue fever 17.52 12.83 9 37606 611 46647836
Ejection fraction decreased 17.27 12.83 42 37573 17895 46630552
Pigmentation disorder 17.22 12.83 18 37597 3715 46644732
Obliterative bronchiolitis 17.13 12.83 13 37602 1762 46646685
Scleroderma-like reaction 17.01 12.83 5 37610 72 46648375
Hypertension 16.94 12.83 91 37524 196265 46452182
Product dose omission issue 16.91 12.83 74 37541 168446 46480001
Hyperkalaemia 16.79 12.83 10 37605 50699 46597748
Lichen planus 16.75 12.83 13 37602 1820 46646627
Disseminated intravascular coagulation 16.72 12.83 43 37572 18962 46629485
Hyperhidrosis 16.63 12.83 29 37586 89279 46559168
Eosinophilia 16.42 12.83 43 37572 19174 46629273
Seizure 16.36 12.83 48 37567 123006 46525441
Fibrin degradation products increased 16.35 12.83 6 37609 178 46648269
Gastrointestinal angiectasia 16.19 12.83 5 37610 86 46648361
Acute graft versus host disease 16.08 12.83 18 37597 4012 46644435
Intentional product misuse 16.03 12.83 9 37606 47119 46601328
Lichenoid keratosis 15.82 12.83 11 37604 1302 46647145
Tumour lysis syndrome 15.80 12.83 24 37591 7212 46641235
Central nervous system leukaemia 15.77 12.83 5 37610 94 46648353
Abortion induced 15.67 12.83 29 37586 10231 46638216
Blood blister 15.62 12.83 12 37603 1656 46646791
Skin hypopigmentation 15.58 12.83 7 37608 353 46648094
Fibromyalgia 15.53 12.83 5 37610 36458 46611989
Therapy partial responder 15.49 12.83 19 37596 4663 46643784
Jaw operation 15.43 12.83 9 37606 786 46647661
Intentional product use issue 15.36 12.83 12 37603 52768 46595679
Metastasis 15.09 12.83 18 37597 4294 46644153
Growth disorder 15.08 12.83 3 37612 6 46648441
Hair colour changes 14.86 12.83 12 37603 1780 46646667
Acute leukaemia 14.81 12.83 10 37605 1128 46647319
Wound 14.81 12.83 8 37607 42794 46605653
Subdural haematoma evacuation 14.77 12.83 3 37612 7 46648440
Therapy interrupted 14.63 12.83 29 37586 10762 46637685
Therapy cessation 14.63 12.83 51 37564 26578 46621869
Cardio-respiratory arrest 14.59 12.83 16 37599 59853 46588594
Hepatic neoplasm 14.56 12.83 12 37603 1832 46646615
Delirium 14.35 12.83 6 37609 37222 46611225
Glossodynia 14.35 12.83 9 37606 44364 46604083
Suicide attempt 14.21 12.83 14 37601 55022 46593425
Vascular malformation 14.21 12.83 5 37610 131 46648316
Irritability 14.18 12.83 3 37612 28943 46619504
Dry skin 14.13 12.83 68 37547 40948 46607499
Primary adrenal insufficiency 13.98 12.83 4 37611 52 46648395
Mobility decreased 13.90 12.83 17 37598 60577 46587870
Gastrectomy 13.84 12.83 7 37608 460 46647987
Osteoarthritis 13.61 12.83 18 37597 62007 46586440
Myeloid maturation arrest 13.56 12.83 3 37612 12 46648435
Dermatofibrosarcoma protuberans 13.56 12.83 3 37612 12 46648435
Leukaemic infiltration extramedullary 13.46 12.83 4 37611 60 46648387
Polymerase chain reaction 13.36 12.83 3 37612 13 46648434
Myelosuppression 13.34 12.83 23 37592 7680 46640767
Toxicity to various agents 13.28 12.83 108 37507 211658 46436789
Adenocarcinoma gastric 13.17 12.83 7 37608 510 46647937
Parakeratosis 13.15 12.83 5 37610 164 46648283
Drug withdrawal syndrome 13.08 12.83 3 37612 27381 46621066
Cystitis 13.07 12.83 9 37606 42232 46606215
Acute myeloid leukaemia recurrent 12.98 12.83 10 37605 1386 46647061
Desmoid tumour 12.88 12.83 4 37611 70 46648377

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2275.57 11.83 2561 37437 354722 29557758
Gastrointestinal stromal tumour 1139.64 11.83 279 39719 1027 29911453
Chronic myeloid leukaemia 982.60 11.83 286 39712 2291 29910189
Drug resistance 746.76 11.83 414 39584 19719 29892761
Blast crisis in myelogenous leukaemia 712.58 11.83 161 39837 373 29912107
Second primary malignancy 588.04 11.83 245 39753 6111 29906369
Malignant neoplasm progression 454.45 11.83 520 39478 71767 29840713
Neoplasm malignant 371.96 11.83 254 39744 17560 29894920
Cytogenetic analysis abnormal 328.00 11.83 82 39916 335 29912145
Philadelphia chromosome positive 277.80 11.83 64 39934 167 29912313
Pleural effusion 200.98 11.83 357 39641 73709 29838771
Gene mutation 193.37 11.83 63 39935 758 29911722
Chromosome analysis abnormal 186.85 11.83 41 39957 78 29912402
Metastases to liver 158.66 11.83 130 39868 11835 29900645
Leukaemia recurrent 157.29 11.83 64 39934 1497 29910983
Drug intolerance 155.85 11.83 243 39755 45048 29867432
Chronic myeloid leukaemia recurrent 154.88 11.83 36 39962 99 29912381
Chronic myeloid leukaemia transformation 150.02 11.83 37 39961 141 29912339
Acute lymphocytic leukaemia recurrent 148.09 11.83 72 39926 2595 29909885
Periorbital oedema 144.33 11.83 76 39922 3250 29909230
Gene mutation identification test positive 122.23 11.83 32 39966 163 29912317
Recurrent cancer 110.95 11.83 46 39952 1130 29911350
Therapeutic response decreased 104.45 11.83 145 39853 24204 29888276
Blast cell crisis 98.49 11.83 23 39975 65 29912415
Muscle spasms 96.74 11.83 245 39753 64593 29847887
Hypotension 95.30 11.83 77 39921 200488 29711992
Oedema 95.02 11.83 190 39808 42803 29869677
Drug abuse 92.50 11.83 4 39994 82068 29830412
Completed suicide 92.19 11.83 12 39986 99480 29813000
Eyelid oedema 91.40 11.83 66 39932 4979 29907501
Chronic graft versus host disease 88.91 11.83 60 39938 4059 29908421
Neoplasm recurrence 87.71 11.83 45 39953 1822 29910658
Acute kidney injury 84.41 11.83 148 39850 273694 29638786
White blood cell count increased 83.70 11.83 172 39826 39501 29872979
Neoplasm progression 82.84 11.83 111 39887 17912 29894568
Overdose 78.54 11.83 10 39988 84327 29828153
Gastric antral vascular ectasia 76.93 11.83 25 39973 298 29912182
Desmoid tumour 74.24 11.83 19 39979 87 29912393
Therapy non-responder 70.94 11.83 135 39863 29318 29883162
Polymerase chain reaction positive 70.77 11.83 18 39980 80 29912400
Face oedema 65.08 11.83 78 39920 11256 29901224
Splenomegaly 65.00 11.83 85 39913 13395 29899085
Necrotising panniculitis 63.34 11.83 14 39984 28 29912452
Prostate cancer 62.94 11.83 114 39884 23843 29888637
Chordoma 61.82 11.83 11 39987 0 29912480
Clonal evolution 61.77 11.83 17 39981 108 29912372
Graft versus host disease 60.17 11.83 71 39927 10079 29902401
Fluid retention 58.25 11.83 113 39885 24885 29887595
Metastases to peritoneum 57.57 11.83 32 39966 1525 29910955
Acquired gene mutation 57.50 11.83 29 39969 1132 29911348
Scleroderma 56.65 11.83 30 39968 1297 29911183
Fall 54.39 11.83 100 39898 181772 29730708
Blast cell count increased 54.30 11.83 27 39971 1022 29911458
Toxicity to various agents 54.26 11.83 96 39902 177087 29735393
Central nervous system leukaemia 53.15 11.83 18 39980 246 29912234
Acute lymphocytic leukaemia 52.95 11.83 39 39959 3033 29909447
Product substitution issue 51.08 11.83 65 39933 9970 29902510
Off label use 51.04 11.83 167 39831 249123 29663357
Bradycardia 49.78 11.83 13 39985 65513 29846967
Bone pain 49.29 11.83 90 39908 18936 29893544
Myelofibrosis 49.27 11.83 29 39969 1542 29910938
Cytogenetic abnormality 48.84 11.83 23 39975 771 29911709
Blast cells present 47.92 11.83 15 39983 157 29912323
Disease progression 47.56 11.83 222 39776 79652 29832828
Accident 47.34 11.83 39 39959 3574 29908906
Confusional state 46.98 11.83 67 39931 134767 29777713
Pituitary apoplexy 46.29 11.83 10 39988 17 29912463
Ascites 45.68 11.83 128 39870 35793 29876687
Typhoid fever 44.91 11.83 10 39988 21 29912459
Endocarditis noninfective 43.89 11.83 13 39985 111 29912369
Bone marrow failure 42.76 11.83 111 39887 29674 29882806
Exposure via father 42.61 11.83 13 39985 124 29912356
Chronic graft versus host disease in skin 41.67 11.83 20 39978 700 29911780
Bone marrow necrosis 41.62 11.83 13 39985 135 29912345
Hyperkalaemia 41.61 11.83 18 39980 65992 29846488
Treatment failure 41.59 11.83 121 39877 34558 29877922
Tumour haemorrhage 41.12 11.83 31 39967 2497 29909983
Intentional overdose 40.91 11.83 4 39994 41477 29871003
Tumour rupture 39.77 11.83 13 39985 158 29912322
Surgery 39.70 11.83 62 39936 11489 29900991
Haemoglobin decreased 38.76 11.83 273 39725 113825 29798655
Loss of therapeutic response 37.55 11.83 11 39987 90 29912390
Somnolence 36.84 11.83 45 39953 96718 29815762
Pulmonary embolism 35.78 11.83 31 39967 78104 29834376
Hallucination 34.92 11.83 11 39987 49048 29863432
Platelet count decreased 34.92 11.83 252 39746 105877 29806603
Colon cancer 34.61 11.83 49 39949 8323 29904157
Drug hypersensitivity 34.12 11.83 25 39973 68494 29843986
Tumour necrosis 33.82 11.83 20 39978 1073 29911407
Gastrectomy 33.41 11.83 11 39987 137 29912343
Gastric cancer 33.35 11.83 37 39961 4913 29907567
Nausea 32.65 11.83 567 39431 296390 29616090
Cardiac arrest 32.46 11.83 46 39952 92804 29819676
Drug interaction 32.22 11.83 147 39851 199421 29713059
Eye swelling 32.05 11.83 49 39949 8915 29903565
Generalised oedema 31.77 11.83 57 39941 11828 29900652
Growth retardation 31.44 11.83 22 39976 1578 29910902
Seizure 31.34 11.83 52 39946 98423 29814057
Pulmonary aplasia 31.29 11.83 6 39992 3 29912477
Pneumonia 31.20 11.83 291 39707 334015 29578465
Tumour excision 31.10 11.83 10 39988 115 29912365
Thrombocytopenia 30.96 11.83 299 39699 136745 29775735
Chloroma 30.80 11.83 14 39984 432 29912048
Syncope 30.74 11.83 41 39957 84862 29827618
Oral pigmentation 29.57 11.83 6 39992 6 29912474
Rhabdomyolysis 29.38 11.83 25 39973 63555 29848925
Delirium 29.12 11.83 9 39989 40622 29871858
Pericardial effusion 28.51 11.83 77 39921 21067 29891413
Malaria 28.17 11.83 11 39987 230 29912250
Renal tuberculosis 28.10 11.83 5 39993 0 29912480
Stem cell transplant 27.91 11.83 23 39975 2108 29910372
Deep vein thrombosis 27.70 11.83 24 39974 60477 29852003
Anxiety 27.18 11.83 49 39949 89822 29822658
Pseudoporphyria 27.04 11.83 11 39987 257 29912223
Blindness 26.68 11.83 54 39944 12255 29900225
Inappropriate schedule of product administration 26.39 11.83 10 39988 39718 29872762
Flushing 26.25 11.83 4 39994 29488 29882992
Psoriasis 26.14 11.83 12 39986 42494 29869986
Dizziness 26.13 11.83 153 39845 194756 29717724
Hyperhidrosis 25.74 11.83 31 39967 67059 29845421
Demyelination 25.72 11.83 24 39974 2596 29909884
Graft versus host disease in eye 25.57 11.83 10 39988 210 29912270
Rash 25.38 11.83 378 39620 191511 29720969
Optic neuritis 25.00 11.83 26 39972 3208 29909272
Cardio-respiratory arrest 24.73 11.83 24 39974 57282 29855198
Plasma cell myeloma 24.73 11.83 21 39977 53441 29859039
Tremor 24.72 11.83 39 39959 75324 29837156
International normalised ratio increased 24.31 11.83 17 39981 47722 29864758
Metabolic acidosis 23.95 11.83 10 39988 37451 29875029
Oedema peripheral 23.93 11.83 231 39767 105601 29806879
Therapy partial responder 23.85 11.83 27 39971 3664 29908816
Therapeutic product effect decreased 23.59 11.83 5 39993 29071 29883409
Large intestine infection 23.49 11.83 17 39981 1286 29911194
Post embolisation syndrome 23.41 11.83 7 39991 62 29912418
Bone marrow transplant 23.07 11.83 15 39983 953 29911527
Right ventricular diastolic collapse 22.92 11.83 7 39991 67 29912413
Chronic obstructive pulmonary disease 22.74 11.83 17 39981 46109 29866371
Intentional product misuse 22.57 11.83 9 39989 34658 29877822
Spleen palpable 22.48 11.83 4 39994 0 29912480
Acute aortic syndrome 22.48 11.83 4 39994 0 29912480
Philadelphia chromosome negative 22.48 11.83 4 39994 0 29912480
Agitation 21.80 11.83 24 39974 54049 29858431
Pemphigus 21.71 11.83 16 39982 1245 29911235
B-cell small lymphocytic lymphoma 21.70 11.83 8 39990 142 29912338
Tachycardia 21.59 11.83 41 39957 73698 29838782
Ocular myasthenia 21.12 11.83 9 39989 237 29912243
Blood pressure increased 21.05 11.83 40 39958 71888 29840592
Haematotoxicity 21.04 11.83 33 39965 6137 29906343
Rectosigmoid cancer 21.01 11.83 8 39990 156 29912324
Epistaxis 20.83 11.83 24 39974 52957 29859523
Tuberculosis 20.65 11.83 38 39960 8039 29904441
Dehydration 20.51 11.83 90 39908 123449 29789031
Transformation to acute myeloid leukaemia 20.46 11.83 12 39986 634 29911846
Bone marrow oedema 20.43 11.83 11 39987 492 29911988
Anaphylactic reaction 20.41 11.83 6 39992 27976 29884504
Aggression 20.35 11.83 12 39986 36895 29875585
Intestinal congestion 20.25 11.83 4 39994 3 29912477
Complications of transplant surgery 20.12 11.83 11 39987 507 29911973
Multiple-drug resistance 19.84 11.83 22 39976 2919 29909561
Concomitant disease aggravated 19.71 11.83 29 39969 5100 29907380
Condition aggravated 19.66 11.83 106 39892 137760 29774720
Periorbital swelling 19.62 11.83 8 39990 188 29912292
Dengue fever 19.58 11.83 8 39990 189 29912291
Suicidal ideation 19.55 11.83 12 39986 36102 29876378
Leukaemia 19.43 11.83 23 39975 3274 29909206
Pancytopenia 19.39 11.83 186 39812 84866 29827614
Blood lactate dehydrogenase increased 19.29 11.83 66 39932 20535 29891945
Urticaria 19.12 11.83 27 39971 54579 29857901
Pericardial excision 18.82 11.83 4 39994 6 29912474
Suicide attempt 18.77 11.83 13 39985 36684 29875796
Drug dependence 18.70 11.83 3 39995 21292 29891188
Neoplasm 18.47 11.83 25 39973 4071 29908409
Marrow hyperplasia 18.34 11.83 13 39985 952 29911528
Dropped head syndrome 18.28 11.83 6 39992 74 29912406
Chest expansion decreased 18.22 11.83 7 39991 140 29912340
Mental status changes 17.85 11.83 14 39984 37065 29875415
Product use in unapproved indication 17.71 11.83 163 39835 73530 29838950
Graft versus host disease in lung 17.51 11.83 10 39988 502 29911978
Bladder cancer 17.48 11.83 38 39960 9064 29903416
Platelet count increased 17.36 11.83 37 39961 8705 29903775
Abscess drainage 17.33 11.83 8 39990 256 29912224
Acinetobacter sepsis 17.28 11.83 5 39993 39 29912441
Gelatinous transformation of the bone marrow 17.21 11.83 4 39994 11 29912469
Pigmentation disorder 16.95 11.83 17 39981 2009 29910471
Janus kinase 2 mutation 16.86 11.83 3 39995 0 29912480
Hepatic embolisation 16.86 11.83 3 39995 0 29912480
Pseudomyxoma peritonei 16.86 11.83 3 39995 0 29912480
Hydrocele operation 16.86 11.83 3 39995 0 29912480
Central nervous system neoplasm 16.85 11.83 5 39993 43 29912437
Therapy change 16.72 11.83 19 39979 2590 29909890
Biopsy bone marrow abnormal 16.61 11.83 8 39990 282 29912198
Blood glucose increased 16.49 11.83 36 39962 61494 29850986
Anaemia 16.37 11.83 378 39620 207614 29704866
Trisomy 8 16.27 11.83 5 39993 49 29912431
Coma 16.25 11.83 18 39980 40431 29872049
Vomiting 16.23 11.83 396 39602 219422 29693058
Medication error 16.23 11.83 4 39994 20968 29891512
Essential thrombocythaemia 16.09 11.83 5 39993 51 29912429
Drug reaction with eosinophilia and systemic symptoms 16.08 11.83 9 39989 28479 29884001
Atrial fibrillation 16.04 11.83 82 39916 108042 29804438
Lactic acidosis 16.04 11.83 11 39987 31202 29881278
Neuropathy peripheral 15.94 11.83 45 39953 70430 29842050
Hyponatraemia 15.88 11.83 42 39956 67160 29845320
Acute myocardial infarction 15.88 11.83 29 39969 52910 29859570
Chills 15.77 11.83 47 39951 72291 29840189
Encephalopathy 15.70 11.83 12 39986 32193 29880287
Disease recurrence 15.63 11.83 48 39950 14113 29898367
Growth failure 15.59 11.83 5 39993 57 29912423
Lung neoplasm malignant 15.52 11.83 50 39948 15082 29897398
Bone marrow disorder 15.47 11.83 14 39984 1456 29911024
Hypereosinophilic syndrome 15.16 11.83 7 39991 224 29912256
Bence Jones proteinuria 14.78 11.83 3 39995 3 29912477
Metastasis 14.67 11.83 20 39978 3278 29909202
Parakeratosis 14.64 11.83 6 39992 143 29912337
Metastases to heart 14.64 11.83 6 39992 143 29912337
Lacrimation increased 14.29 11.83 30 39968 6986 29905494
Hyperchromic anaemia 14.08 11.83 4 39994 29 29912451
Blood pressure decreased 13.93 11.83 26 39972 47049 29865431
Product dose omission issue 13.87 11.83 69 39929 91562 29820918
Insomnia 13.72 11.83 71 39927 93265 29819215
Cellulitis 13.70 11.83 26 39972 46758 29865722
Lymphocytic infiltration 13.68 11.83 9 39989 583 29911897
Ejection fraction decreased 13.67 11.83 48 39950 15127 29897353
Stress 13.59 11.83 5 39993 20230 29892250
Transitional cell carcinoma 13.59 11.83 15 39983 1980 29910500
Laryngeal cancer stage III 13.57 11.83 3 39995 6 29912474
Fibrin D dimer decreased 13.57 11.83 3 39995 6 29912474
Aspiration bone marrow 13.57 11.83 3 39995 6 29912474
Clear cell sarcoma of soft tissue 13.57 11.83 3 39995 6 29912474
Bladder neoplasm surgery 13.32 11.83 4 39994 36 29912444
Wheezing 13.29 11.83 13 39985 30925 29881555
Tumour compression 13.25 11.83 5 39993 95 29912385
Therapy responder 13.23 11.83 6 39992 184 29912296
Colitis 13.19 11.83 13 39985 30807 29881673
Lipase increased 13.13 11.83 33 39965 8643 29903837
Cancer surgery 13.13 11.83 8 39990 453 29912027
Cytopenia 13.13 11.83 32 39966 8224 29904256
Skin neoplasm excision 13.10 11.83 7 39991 308 29912172
Angioedema 13.06 11.83 16 39982 34368 29878112
Erythropoiesis abnormal 13.03 11.83 6 39992 191 29912289
Blast cell proliferation 12.97 11.83 3 39995 8 29912472
Paternal exposure during pregnancy 12.97 11.83 3 39995 8 29912472
Unevaluable event 12.93 11.83 14 39984 31771 29880709
Hyperkeratosis 12.93 11.83 19 39979 3338 29909142
Thrombosis 12.78 11.83 23 39975 42208 29870272
Intentional product use issue 12.77 11.83 18 39980 36422 29876058
Bone development abnormal 12.77 11.83 4 39994 42 29912438
Swelling of eyelid 12.58 11.83 7 39991 334 29912146
Ileus paralytic 12.51 11.83 25 39973 5623 29906857
Breast oedema 12.47 11.83 3 39995 10 29912470
Polycythaemia vera 12.47 11.83 6 39992 211 29912269
Myasthenia gravis crisis 12.41 11.83 7 39991 343 29912137
Arterial intramural haematoma 12.36 11.83 4 39994 47 29912433
Skin depigmentation 12.32 11.83 7 39991 348 29912132
Myositis 12.23 11.83 36 39962 10341 29902139
Leukocytosis 12.22 11.83 59 39939 21443 29891037
Oropharyngeal pain 12.21 11.83 12 39986 28484 29883996
Haemorrhagic ascites 12.20 11.83 5 39993 119 29912361
Hepatotoxicity 11.95 11.83 52 39946 18093 29894387
Constipation 11.93 11.83 95 39903 112811 29799669
Metastases to lymph nodes 11.83 11.83 20 39978 3957 29908523

Pharmacologic Action:

SourceCodeDescription
ATC L01EA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:68495 type i programmed cell-death inducer
CHEBI has role CHEBI:149553 anti-coronaviral agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Dermatofibrosarcoma protuberans indication 276799004
Systemic mast cell disease indication 397016004 DOID:349
Blastic phase chronic myeloid leukemia indication 413656006
Chronic eosinophilic leukemia indication 413836008
Chronic phase chronic myeloid leukemia indication 413847001
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Idiopathic hypereosinophilic syndrome indication 423294001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Myelodysplastic/ Myeloproliferative Diseases associated with Platelet-derived Growth Factor Receptor indication
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Heart valve disorder contraindication 368009 DOID:4079
Cerebral edema contraindication 2032001
Hypophosphatemia contraindication 4996001
Congenital heart disease contraindication 13213009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Pulmonary edema contraindication 19242006 DOID:11396
Hypertensive disorder contraindication 38341003 DOID:10763
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Purpuric disorder contraindication 387778001
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Pleural Effusions contraindication
Chronic Heart Failure Following Myocardial Infarction contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.96 acidic
pKa2 8.49 Basic
pKa3 4.34 Basic
pKa4 3.73 Basic
pKa5 2.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.89 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.96 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Ephrin type-B receptor 4 Kinase Ki 5 PDSP
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5 PDSP
Insulin receptor Kinase AGONIST Ki 5 PDSP
Tyrosine-protein kinase JAK2 Kinase Ki 5 PDSP
Sodium-dependent serotonin transporter Transporter Ki 6.13 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.27 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.71 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 6.70 DRUG MATRIX
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Mitogen-activated protein kinase 10 Kinase Kd 5.51 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.59 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.20 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.12 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 7.52 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.14 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.28 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 4.59 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Ki 4.51 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.51 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.38 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.59 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase SYK Kinase IC50 5.30 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.48 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.62 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.82 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.35 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.11 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 5.37 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.02 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.46 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 7.40 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 5.55 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.68 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.06 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
Lysine--tRNA ligase Enzyme Ki 5.30 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.01 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.22 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.34 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.28 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.49 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.51 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 7.40 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.96 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.82 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.40 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.15 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.40 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.28 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 4.69 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.47 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 6.33 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 6.96 CHEMBL
Bcr/Abl fusion protein Kinase Ki 7.85 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.12 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 5.26 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.50 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.77 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.41 CHEMBL
Platelet-derived growth factor receptor Kinase IC50 7.30 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5 PDSP
Mitogen-activated protein kinase 14 Kinase IC50 4.86 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5 PDSP
Ephrin type-B receptor 1 Kinase Ki 5 PDSP
Carbonic anhydrase 13 Enzyme Ki 5.13 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 5.56 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 7.97 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.11 CHEMBL

External reference:

IDSource
4021257 VUID
N0000148698 NUI
D01441 KEGG_DRUG
220127-57-1 SECONDARY_CAS_RN
4021257 VANDF
4021258 VANDF
C0385728 UMLSCUI
CHEBI:31690 CHEBI
STI PDB_CHEM_ID
CHEMBL941 ChEMBL_ID
CHEMBL1642 ChEMBL_ID
DB00619 DRUGBANK_ID
D000068877 MESH_DESCRIPTOR_UI
5291 PUBCHEM_CID
5687 IUPHAR_LIGAND_ID
8031 INN_ID
BKJ8M8G5HI UNII
282386 RXNORM
16030 MMSL
238904 MMSL
41395 MMSL
d04758 MMSL
009151 NDDF
009152 NDDF
129558005 SNOMEDCT_US
391634008 SNOMEDCT_US
414460008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7629 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7630 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6621 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6901 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
imatinib mesylate Human Prescription Drug Label 1 16714-704 TABLET, FILM COATED 100 mg ORAL ANDA 29 sections
imatinib mesylate Human Prescription Drug Label 1 16714-705 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-043 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-044 TABLET, FILM COATED 400 mg ORAL ANDA 27 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-344 TABLET 100 mg ORAL ANDA 26 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-345 TABLET 400 mg ORAL ANDA 26 sections
imatinib mesylate Human Prescription Drug Label 1 47335-472 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
imatinib mesylate Human Prescription Drug Label 1 47335-475 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50268-426 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50268-427 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 51407-269 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 51407-270 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
IMATINIB MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 51991-376 TABLET, COATED 100 mg ORAL ANDA 33 sections
IMATINIB MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 51991-377 TABLET, COATED 400 mg ORAL ANDA 33 sections
Imatinib Mesylate Human Prescription Drug Label 1 59651-240 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate Human Prescription Drug Label 1 59651-241 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 59923-723 TABLET, COATED 100 mg ORAL ANDA 32 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 59923-724 TABLET, COATED 400 mg ORAL ANDA 32 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60429-925 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60429-926 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections